Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Assets Average: 2011-2025

Historic Assets Average for Sunshine Biopharma (SBFM) over the last 9 years, with Sep 2025 value amounting to $31.7 million.

  • Sunshine Biopharma's Assets Average rose 6.90% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $29.0 million for FY2024, which is 2.33% up from last year.
  • Per Sunshine Biopharma's latest filing, its Assets Average stood at $31.7 million for Q3 2025, which was up 3.76% from $30.6 million recorded in Q2 2025.
  • Sunshine Biopharma's Assets Average's 5-year high stood at $41.4 million during Q3 2022, with a 5-year trough of $1.5 million in Q1 2021.
  • In the last 3 years, Sunshine Biopharma's Assets Average had a median value of $29.7 million in 2024 and averaged $29.4 million.
  • In the last 5 years, Sunshine Biopharma's Assets Average skyrocketed by 1,818.40% in 2022 and then plummeted by 32.34% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Assets Average (Quarterly) stood at $2.4 million in 2021, then spiked by 1,390.14% to $35.1 million in 2022, then dropped by 21.55% to $27.5 million in 2023, then increased by 10.22% to $30.3 million in 2024, then grew by 6.90% to $31.7 million in 2025.
  • Its Assets Average was $31.7 million in Q3 2025, compared to $30.6 million in Q2 2025 and $29.9 million in Q1 2025.